Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Boston, MA

157 studies for Breast Cancer are recruiting at 308 sites within 50 miles of Boston, Massachusetts, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Boston.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Boston

Showing the 50 nearest of 157 studies.
  1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    16 sites within 50 mi
  2. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Boston Medical Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  3. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    NCT04893109

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 50 mi
  4. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Boston Medical Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 50 mi
  5. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Boston Medical Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 50 mi
  6. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  7. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All

    Nearest sites: Tufts Medical Center (Boston, MA); Tufts Medical Center Cancer Center Stoneham (Stoneham, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  8. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Lahey Clinic (Burlington, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  9. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Beth Israel Deaconess Medical Center,East Campus Research Pharmacy (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  10. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Tufts Medical Center (Boston, MA); Lahey Clinic (Burlington, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  11. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    NCT06377852

    • Phase 3
    • Ages 60 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Dana-Farber Brigham Cancer Center at South Shore Health (Weymouth, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  12. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Tufts Medical Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  13. Sacituzumab Govitecan In TNBC

    NCT04230109

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  14. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    NCT04468061

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); DF/BWCC in Clinical Affiliation with South Shore Hospital (South Weymouth, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  15. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    NCT05503797

    • Phase 2
    • Ages 8 years and older
    • Sex: All

    Nearest sites: Massachusetts General Hospital (Boston, MA); Tufts Medical Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  16. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    NCT05579366

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  17. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    NCT05696626

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  18. Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

    NCT02290834

    • Interventional
    • Ages 60 years and older
    • Sex: Female
    • Accepts healthy volunteers

    Nearest sites: Massachusetts General Hospital (Boston, MA); Massachusetts General Hospital/North Shore Cancer Center (Salem, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  19. CONFIRM: Magnetic Resonance Guided Radiation Therapy

    NCT04368702

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham & Women's Hospital (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  20. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  21. Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

    NCT04899908

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham and Women's Hospital (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  22. Scalp Cooling in MBC

    NCT04986579

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham and Women's Hospital (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  23. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    NCT05216432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  24. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    NCT05377996

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  25. VS-6766+Abema+Fulv in Met HR+/HER- BC

    NCT05608252

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Brigham and Women's Hospital (Boston, MA); Dana Farber Cancer Institite (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

    NCT05625659

    • Interventional
    • Ages 45 to 74 years
    • Sex: Female
    • Accepts healthy volunteers

    Nearest sites: Massachusetts General Hospital (Boston, MA); Boston Breast Diagnostic Center (Wellesley Hills, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  27. A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

    NCT05683418

    • Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  28. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    NCT05768139

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  29. TRUDI: TDXD+Durva in HER2+/Low IBC

    NCT05795101

    • Phase 2
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Brigham and Women's Hospital (Boston, MA); Dana Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  30. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    NCT05877599

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Boston, MA); Research Site (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  31. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    NCT05983432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  32. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    NCT06150664

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  33. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    NCT06253871

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  34. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

    NCT06369285

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  35. A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

    NCT06435429

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Rhode Island Hospital (Providence, RI)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  36. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    NCT06625775

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Insitute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  37. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    NCT06638307

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital Cancer Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  38. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

    NCT06657222

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  39. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    NCT06784193

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  40. SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

    NCT06896474

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Brigham and Women's Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  41. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

    NCT06926868

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana-Farber Cancer Institute (Boston, MA); Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  42. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    NCT06966700

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute ( Site 0090) (Boston, MA); Massachusetts General Hospital Cancer Center ( Site 0091) (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  43. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Dana Farber Cancer Institute (Boston, MA); Tufts Medical Center (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  44. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    NCT06993844

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Beth Israel Deaconess Medical Center (Boston, MA); Dana-Farber Cancer Institute (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  45. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    NCT07182149

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Normunity Investigational Site (Boston, MA); Normunity Investigational Site (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  46. Prospective Screening for Breast Cancer-related Lymphedema

    NCT01521741

    • Observational
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Massachusetts General Hospital (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. The Cancer of the Pancreas Screening-5 CAPS5)Study

    NCT02000089

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Dana Farber Cancer Center, Harvard University (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

    NCT02610413

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Eastern Cooperative Oncology Group (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

    NCT02610426

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Eastern Cooperative Oncology Group (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

    NCT02610439

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Eastern Cooperative Oncology Group (Boston, MA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.